Predict your next investment

HEALTHCARE | Biotechnology
noxxon.com

See what CB Insights has to offer

Business Relationships

4

Service Providers

3

NOXXON Pharma Service Providers

3 Service Providers

NOXXON Pharma has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Series F

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Series F

Provider Type

Accounting Firm

Subscribe to see more

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

NOXXON Pharma Partners & Customers

4 Partners and customers

NOXXON Pharma has 4 strategic partners and customers. NOXXON Pharma recently partnered with Aptarion on January 1, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

1/4/2017

Licensee

Aptarion

Germany

04.01.17 - NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Berlin , Germany , January 04 , 2017 - NOXXON Pharma N.V. , a biotechnology company whose core focus is on cancer treatment , has today announced an agreement with Aptarion to license enabling technology , assign certain preclinical and technology research programs and transfer lab assets in exchange for cash , royalties and an equity stake in Aptarion ... NOXXON Pharma N.V. has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs .

1

12/15/2016

Partner

Merck & Co.

United States

Subscribe to see more

Subscribe to see more

10

6/11/2008

Licensee

Eli Lilly and Company

United States

Subscribe to see more

Subscribe to see more

10

3/23/2006

Licensee

Pfizer

United States

Subscribe to see more

Subscribe to see more

10

Date

1/4/2017

12/15/2016

6/11/2008

3/23/2006

Type

Licensee

Partner

Licensee

Licensee

Business Partner

Aptarion

Merck & Co.

Eli Lilly and Company

Pfizer

Country

Germany

United States

United States

United States

News Snippet

04.01.17 - NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Berlin , Germany , January 04 , 2017 - NOXXON Pharma N.V. , a biotechnology company whose core focus is on cancer treatment , has today announced an agreement with Aptarion to license enabling technology , assign certain preclinical and technology research programs and transfer lab assets in exchange for cash , royalties and an equity stake in Aptarion ... NOXXON Pharma N.V. has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.